Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study

被引：0
|
作者：
Dong, P. [1 ]
Huang, T. [1 ]
Jiang, L. [1 ]
Wei, W. [1 ]
Zheng, X. [1 ]
Zhang, Z. [1 ]
Guo, S. [1 ]
Han, H. [1 ]
Zhou, F. [1 ]
机构：
[1] Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219P
引用
收藏
页码：S1560 / S1561
页数：2
相关论文
共 50 条
  • [1] Clinical effectiveness and safety of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): a single-center retrospective study
    Zhong, Xi
    Huang, Tingxuan
    Peng, Yulu
    Wei, Wensu
    Zhang, Zhiling
    Han, Hui
    Dong, Pei
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [2] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [3] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
  • [4] First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
    Chaudhuri, T.
    Upadhyay, A.
    Bankira, J.
    Panda, R.
    Pandey, V.
    Mitra, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1567 - S1567
  • [5] Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab
    Doshi, Gurjyot K.
    Robert, Nicholas J.
    Chen, Liwei
    Chan, Philip K.
    Del Tejo, Viviana
    Stwalley, Brian
    Huo, Stephen
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [6] Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
    Zhong, Xi
    Huang, Tingxuan
    Peng, Yulu
    Ng, Cheoklong
    Liu, Xuhao
    Jing, Taile
    Wei, Wensu
    Zhang, Zhiling
    Han, Hui
    Chen, Minfeng
    He, Liru
    Huang, Jiwei
    Dong, Pei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Dudani, Shaan
    Steinharter, John A.
    McGregor, Bradley A.
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron R.
    Iafolla, Marco A. J.
    Zanotti, Giovanni
    Huynh, Lynn
    Chang, Rose
    Duh, Mei S.
    Heng, Daniel Y. C.
    ONCOLOGIST, 2020, 25 (05): : 422 - 430
  • [8] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [9] Real-world (RW) clinical outcomes for metastatic renal cell carcinoma (mRCC)
    George, S.
    Faccone, J.
    Huo, S.
    Zhang, Y.
    Stwalley, B.
    Hamilton, M.
    Le, T. K.
    Ejzykowicz, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S701 - S702
  • [10] Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
    Geynisman, Daniel M.
    Faccone, Jillian
    Zhang Ying
    Ejzykowicz, Flavia
    Stwalley, Brian
    Hamilton, Melissa
    Le, Trong Kim
    Huo, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345